Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for inhibiting expression of the lect2 gene

a technology of lect2 and expression inhibition, applied in the direction of drug composition, dermatological disorder, nervous disorder, etc., can solve the problems of limited treatment options and need for lect2 amyloidosis treatment, and achieve the effect of preventing at least one symptom, and reducing lect2 gene expression

Inactive Publication Date: 2021-04-01
ALNYLAM PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods for preventing symptoms in subjects with diseases or disorders that would benefit from reducing the expression of the LECT2 gene. The methods involve administering a prophylactically effective amount of an antisense polynucleotide agent or a pharmaceutical composition of the invention. This can reduce amyloid deposition and symptoms associated with it, as well as decrease the levels of the LECT2 protein. Additionally, the invention also provides non-antisense polynucleotide therapeutic agents that can effectively treat the disorder or symptoms.

Problems solved by technology

Treatments for LECT2 amyloidosis are limited, and new treatments are needed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for inhibiting expression of the lect2 gene
  • Compositions and methods for inhibiting expression of the lect2 gene
  • Compositions and methods for inhibiting expression of the lect2 gene

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antisense Synthesis

[0524]The antisense polynucleotides targeting LECT2 were synthesized using standard synthesis methods known in the art.

[0525]A detailed list of modified and unmodified antisense molecules targeting LECT2 is shown in Table 3, including the starting position and mRNA sequence of the antisense oligonucleotide relative to SEQ ID NO: 1.

example 2

In vitro Screening

[0526]In vitro screening of the antisense polynucleotides was performed by transfecting human primary hepatocytes with a single 500 nM dose of an antisense LECT2 polynucleotide using methods known in the art. 32000 cells / well in a 96 well plate were transfected for 24 hours in 0.4 μl RNAiMAX / well. A single dose transfection screen in cells transfected with the indicated antisense polynucleotide is shown in Table 4. The relative LECT2 mRNA expression relative to a mock transfected control was determined.

TABLE 2Abbreviations of nucleotide monomers used in nucleicacid sequence representation. It will be understoodthat these monomers, when present in an oligonucleotide,are mutually linked by 5′-3′-phosphodiester bonds.AbbreviationNucleotide(s)AAdenosine-3′-phosphateAf2′-fluoroadenosine-3′-phosphateAfs2′-fluoroadenosine-3′-phosphorothioateAsadenosine-3′-phosphorothioatea2′-O-methyladenosine-3′-phosphateas2′-O-methyladenosine-3′-phosphorothioateCcytidine-3′-phosphatedA2′...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to antisense polynucleotide agents targeting the LECT2 gene, and methods of using such anti sense polynucleotide agents to inhibit expression of LECT2 and to treat subjects having a LECT2-associated disease, e.g., amyloidosis.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 15 / 564,288, filed Oct. 4, 2017, which is a U.S. National Stage Application under 35 U.S.C. § 371 of International Application No. PCT / US2016 / 026676, filed Apr. 8, 2016, which claims the benefit of U.S. Provisional Application No. 62 / 144,695, filed Apr. 8, 2015, the contents of which are hereby incorporated by reference in their entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 6, 2016, is named A2038-7221WO_SL.txt and is 96,680 bytes in size.FIELD OF THE INVENTION[0003]The invention relates to the specific inhibition of the expression of the LECT2 gene.BACKGROUND OF THE INVENTION[0004]Amyloidosis is a group of diseases characterized by deposition of insoluble fibrous protein aggregates, called amylo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113A61P25/28A61P17/00A61K31/712A61K31/7125A61K47/26
CPCC12N15/1136A61P25/28A61P17/00A61P1/16A61K31/7125A61K47/26A61K31/712C12N2310/11C12N2310/315C12N2310/351C12N2310/322C12N2310/3533C12N2310/335C12N2310/3521C12N2310/321
Inventor HINKLE, GREGORY
Owner ALNYLAM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com